Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05696353 · ClinicalTrials.gov registry record · Phase 3

Teen Driving Translation Study (NIH)

A Phase 3 study of Communication and Recidivism, sponsored by Ginger Yang.

Recruiting
Registry status
Phase 3
Development phase
580
Enrollment target
1
Study location

NCT05696353: Recruiting Phase 3 study of Communication and Recidivism, sponsored by Ginger Yang.

NCT05696353 is a Phase 3 study of Communication and Recidivism that is actively recruiting participants, run by Ginger Yang. The registered enrollment target is 580 participants, below the 1,404-participant average among 34 other Communication trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05696353, a Phase 3 study of Communication and Recidivism, is actively recruiting participants, sponsored by Ginger Yang.

RECRUITING
Registry status
Phase 3
Development phase
580 participants
Enrollment target
1
Study location

Study Summary

To translate our evidence-based, parent-engagement safe teen driving intervention to a high-risk, rural and urban teen drivers with a traffic violation, and to test the implementation, effectiveness, and cost-effectiveness of the proposed intervention.

Primary Outcome

Risky driving events are continuously monitored for teens across all three groups using an in-vehicle device and smartphone app. The system automatically detects and records driving events, including hard braking (≤ -0.45 g-force) sudden acceleration (\> 0.35 g-force), speeding (\>10 miles over the posted speed limit), and speed \>75 mph. Event rates are calculated as the number of risky driving events per 1,000 miles driven.

Interventions

  • COMBINATION_PRODUCT In-vehicle Device
  • BEHAVIORAL Expert-Delivered Parent Communication Training
  • BEHAVIORAL Peer-Delivered Parent Communication Training

Study Locations (1)

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 580 participants
Start Date 2022-11-17
Est. Completion 2026-08-31
Phase Phase 3
Ginger Yang

3 total trials

What NCT05696353 shows while recruiting

NCT05696353 is an interventional study that assigns participants to a tested intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 34 other Communication trials with a reported enrollment target (59% lower).

The record links to 4 conditions, with Communication appearing as the primary indexed condition, and to 3 interventions - of which In-vehicle Device is the first listed.

NCT05696353 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05696353 about?

NCT05696353 is a clinical study titled "Teen Driving Translation Study (NIH)". To translate our evidence-based, parent-engagement safe teen driving intervention to a high-risk, rural and urban teen drivers with a traffic violation, and to test the implementation, effectiveness, and cost-effectiveness of the proposed intervention.

What is the current status of trial NCT05696353?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 580 participants. The study started on 2022-11-17. Estimated completion is 2026-08-31.

What conditions does trial NCT05696353 study?

This clinical trial studies the following conditions: Communication, Recidivism, Drive, Feedback, Psychological.

What interventions are being tested in trial NCT05696353?

The interventions under investigation include: In-vehicle Device (COMBINATION_PRODUCT), Expert-Delivered Parent Communication Training (BEHAVIORAL), Peer-Delivered Parent Communication Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT05696353?

This trial is sponsored by Ginger Yang, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05696353 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Communication

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05696353's enrollment target sits among peer trials

580 10th of 34 higher than 25 of 34 other Communication trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Communication trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04575935 · 580 participants · Phase 3

    Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

  • NCT05143177 · 580 participants · Phase 2

    A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

  • NCT06578104 · 580 participants

    PULSED AF Post-Approval Study

  • NCT06647303 · 580 participants · NA

    Improving Surgical Communication for Patients in Wisconsin

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05696353, the US trial registry maintained by the National Library of Medicine. NCT05696353 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.